Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCC NASDAQ:ERAS NASDAQ:RZLT NASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$2.23+12.1%$1.52$1.09▼$7.66$141.30M2.941.33 million shs4.06 million shsERASErasca$1.45-4.6%$1.38$1.01▼$3.45$430.60M1.051.64 million shs600,082 shsRZLTRezolute$5.26+0.2%$4.21$2.22▼$6.19$448.98M1.03661,631 shs357,794 shsTECXTectonic Therapeutic$22.64+4.2%$21.40$13.70▼$61.07$405.57M3.17187,311 shs382,397 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics-1.49%+33.56%+26.75%+60.48%-60.20%ERASErasca-1.30%+10.14%-5.59%+22.58%-43.28%RZLTRezolute-0.57%+9.95%+19.59%+112.55%+22.09%TECXTectonic Therapeutic+0.79%-0.11%-13.67%+34.41%+37.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCCCC4 Therapeutics3.0309 of 5 stars3.34.00.00.03.31.70.6ERASErasca3.1953 of 5 stars3.52.00.00.03.02.51.3RZLTRezolute2.7699 of 5 stars3.61.00.00.03.24.20.0TECXTectonic Therapeutic3.3974 of 5 stars3.71.00.00.03.15.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.50Moderate Buy$12.00438.12% UpsideERASErasca 3.00Buy$4.57215.27% UpsideRZLTRezolute 3.14Buy$11.83124.97% UpsideTECXTectonic Therapeutic 3.33Buy$83.60269.26% UpsideCurrent Analyst Ratings BreakdownLatest CCCC, RZLT, ERAS, and TECX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025TECXTectonic TherapeuticRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$76.006/6/2025TECXTectonic TherapeuticLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$87.006/5/2025TECXTectonic TherapeuticLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/15/2025TECXTectonic TherapeuticMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$51.00 ➝ $85.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/14/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/28/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/21/2025TECXTectonic TherapeuticMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$51.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$35.58M4.45N/AN/A$3.06 per share0.73ERASErascaN/AN/AN/AN/A$1.50 per shareN/ARZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/ATECXTectonic TherapeuticN/AN/AN/AN/A$9.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$105.32M-$1.47N/AN/AN/A-259.60%-45.86%-28.96%7/30/2025 (Estimated)ERASErasca-$161.65M-$0.62N/AN/AN/AN/A-36.56%-31.08%8/11/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)TECXTectonic Therapeutic-$57.98M-$7.31N/AN/AN/AN/A-30.13%-27.52%8/13/2025 (Estimated)Latest CCCC, RZLT, ERAS, and TECX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CCCCC4 Therapeutics-$0.41N/AN/AN/A$5.24 millionN/A5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/13/2025Q3 2025RZLTRezolute-$0.22-$0.27-$0.05-$0.27N/AN/A5/8/2025Q1 2025TECXTectonic Therapeutic-$1.10-$0.93+$0.17-$0.93N/AN/A5/7/2025Q1 2025CCCCC4 Therapeutics-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A5.705.70ERASErascaN/A12.3512.35RZLTRezoluteN/A8.438.43TECXTectonic TherapeuticN/A22.9222.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%ERASErasca67.78%RZLTRezolute82.97%TECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics8.73%ERASErasca14.40%RZLTRezolute18.39%TECXTectonic Therapeutic38.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics15071.01 million64.81 millionOptionableERASErasca120283.29 million242.49 millionOptionableRZLTRezolute4085.52 million69.79 millionOptionableTECXTectonic Therapeutic12018.67 million11.58 millionN/ACCCC, RZLT, ERAS, and TECX HeadlinesRecent News About These CompaniesTectonic Therapeutic (NASDAQ:TECX) Rating Increased to Hold at Wall Street ZenJuly 6, 2025 | americanbankingnews.comTectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $83.60 Average PT from AnalystsJuly 6, 2025 | americanbankingnews.comTectonic Therapeutic (NASDAQ:TECX) Upgraded to "Hold" at Wall Street ZenJuly 5, 2025 | marketbeat.comTectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of "Buy" from BrokeragesJuly 3, 2025 | marketbeat.comTectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution - NasdaqJuly 1, 2025 | nasdaq.comTectonic Therapeutic joins Russell 3000 indexJune 30, 2025 | msn.comTectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual ReconstitutionJune 30, 2025 | quiverquant.comQTectonic Therapeutic Joins Russell 3000® IndexJune 30, 2025 | globenewswire.comRaymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform RatingJune 25, 2025 | msn.comTectonic Therapeutic (NASDAQ:TECX) Stock Rating Lowered by Wall Street ZenJune 21, 2025 | marketbeat.comWe Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business GrowthJune 15, 2025 | finance.yahoo.comTectonic Therapeutic (NASDAQ:TECX) Coverage Initiated by Analysts at Raymond JamesJune 11, 2025 | marketbeat.comTectonic Therapeutics (TECX) Gains Outperform Rating from Raymond James | TECX Stock NewsJune 10, 2025 | gurufocus.comLifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform RecommendationJune 7, 2025 | msn.comTectonic Therapeutic Holds 2025 Annual Stockholders MeetingJune 6, 2025 | tipranks.comTectonic Therapeutic (TECX) Receives Outperform Rating and $87 Price Target | TECX Stock NewsJune 5, 2025 | gurufocus.comTectonic Therapeutic Reports Q1 2025 Financial ResultsMay 30, 2025 | tipranks.comPromising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45May 22, 2025 | tipranks.comTectonic Therapeutic Announces Phase 1b Trial ResultsMay 19, 2025 | tipranks.comPromising Phase 1b Results and Favorable Safety Profile Justify Buy Rating for Tectonic TherapeuticMay 19, 2025 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Amgen (AMGN)May 17, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCCC, RZLT, ERAS, and TECX Company DescriptionsC4 Therapeutics NASDAQ:CCCC$2.23 +0.24 (+12.06%) Closing price 04:00 PM EasternExtended Trading$2.28 +0.04 (+2.02%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Erasca NASDAQ:ERAS$1.45 -0.07 (-4.61%) Closing price 04:00 PM EasternExtended Trading$1.43 -0.02 (-1.10%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Rezolute NASDAQ:RZLT$5.26 +0.01 (+0.19%) Closing price 04:00 PM EasternExtended Trading$5.27 +0.01 (+0.19%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Tectonic Therapeutic NASDAQ:TECX$22.64 +0.92 (+4.24%) Closing price 04:00 PM EasternExtended Trading$22.66 +0.02 (+0.09%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
